Researchers at Mount Sinai have developed a novel approach to cancer immunotherapy, injecting immune stimulants directly into a tumor to teach the immune system to destroy it and other tumor cells throughout the body.
The “in situ vaccination” worked so well in patients with advanced-stage lymphoma that it is also undergoing trials in breast and head and neck cancer patients, according to a study published in Nature Medicine in April.
The treatment consists of administering a series of immune stimulants directly into one tumor site. The first stimulant recruits important immune cells called dendritic cells that act like generals of the immune army. The second stimulant activatesthe dendritic cells, which then instruct T cells, the immune system’s soldiers, to kill cancer cells and spare non-cancer cells. This immune army learns to recognize features of the tumor cells so it can seek them out and destroy them throughout the body, essentially turning the tumor into a cancer vaccine factory.
“The in situ vaccine approach has broad implications for multiple types of cancer,” said lead author Joshua Brody, MD, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. “This method could also increase the success of other immunotherapies such as checkpoint blockade.”
After testing the lymphoma vaccine in the lab, it was tested in 11 patients in a clinical trial. Some patients had full remission from months to years. In lab tests in mice, the vaccine drastically increased the success of checkpoint blockade immunotherapy, the type of immunotherapy responsible for the complete remission of former President Jimmy Carter’s cancer and the focus of the 2018 Nobel Prize in Medicine.
A clinical trial for lymphoma, breast, and head and neck cancer patients opened in March to test the vaccine with checkpoint blockade drugs. Because the combined immune therapy was at least three times more powerful than either checkpoint blockade or the vaccine by themselves, researchers are extremely optimistic about how effective this may be in patients in this new trial. The in situ vaccine is also being tested in the lab in liver and ovarian cancer.
The Latest on: Cancer immunotherapy
via Google News
The Latest on: Cancer immunotherapy
- Why Brazil may have an advantage at mitigating bladder cancer drug shortageon September 6, 2019 at 10:58 am
Finding alternatives to to help mitigate the worldwide shortage of the bladder cancer immunotherapy Bacillus Calmette-Guerin has been top-of-mind for many health experts, according to Medscape. There ...
- Preclinical study reveals the impact of age on immunotherapy treatment for breast canceron September 6, 2019 at 9:46 am
Recent clinical trials have indicated that immune checkpoint blockade (ICB) therapy, which is designed to unleash a patient's immune system to attack cancer, has been revolutionary in its ...
- Researchers characterize lung inflammation associated with some cancer immnunotherapyon September 6, 2019 at 8:10 am
But among patients with non-small cell lung cancer (NSCLC) who receive checkpoint inhibitor immunotherapy, recent reports suggest that up to 19% may develop a dangerous complication: an inflammation ...
- Improving cancer immunotherapy through nanotechnologyon September 6, 2019 at 3:30 am
The 2018 Nobel Prize in Physiology or Medicine was awarded to pioneers in the field of cancer immunotherapy, as the utility of leveraging a patient’s coordinated and adaptive immune system to fight ...
- Immunotherapy: The Future of Cancer Treatmenton September 5, 2019 at 3:00 am
As an oncologist, nothing makes me happier than to find a therapy that works for one of my patients – something that halts that patient's cancer in its tracks. So I am particularly excited by recent ...
- Immunotherapy for Colon Canceron September 4, 2019 at 5:00 pm
This year it’s estimated that more than 100,000 new cases of colon cancer and an estimated 44,180 new cases of rectal cancer will be diagnosed in the U.S., according to the American Cancer Society.
- IMV Announces Research Collaboration with The Wistar Institute to Develop New Targeted Immunotherapy Against the Common BRAF Cancer Mutationon September 4, 2019 at 4:05 am
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage immuno-oncology company, today announced a collaboration with The Wistar Institute and Meenhard Herlyn, D.V.M., D.Sc., professor in the Molecular ...
- Fate Therapeutics Announces FDA Clearance of IND Application for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer Immunotherapyon September 3, 2019 at 6:01 am
FT596 Product Candidate Derived from Clonal Master iPSC Line Engineered with Three Anti-Tumor Functional Components Designed to Overcome CD19 Antigen Escape and Improve Durability of Response by ...
- Celgene Strikes Cancer Immunotherapy Deal With Immatics For Up To $1.59Bon August 28, 2019 at 11:37 am
Celgene Corporation (NASDAQ: CELG), which has agreed to be acquired by Bristol-Myers Squibb Co (NYSE: BMY), has struck a cell therapy deal with the German biotech Immatics Biotechnologies GmbH ...
- Cancer Immunotherapy Market is Expected to Touch a Value of US$ 145 Billion By 2024on August 28, 2019 at 11:22 am
Aug 28, 2019 (Heraldkeepers) -- New York, August 28, 2019: The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the ...
via Bing News